Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Dr. Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Great Ormond Street Hospital | United Kingdom

Kimberly Coughlan Gilmour is a leading expert in immunology, molecular diagnostics, and cell-based therapeutic development. Her early academic work contributed foundational insights into cytokine signaling, particularly the regulation of the Interferon Regulatory Factor-1 (IRF-1) gene and the signal transduction pathways activated by prolactin and interleukin-2. During her postdoctoral research, she investigated mechanisms governing thymocyte proliferation and differentiation using retroviral manipulation of murine thymic organ cultures, advancing understanding of T-cell development.

Gilmour has played a pivotal role in the evolution of clinical immunology diagnostics, leading the development of national services for the molecular diagnosis of primary immunodeficiency disorders. She has been instrumental in translating complex research methodologies—including gene expression analysis, retroviral and lentiviral transduction, and thymus tissue culture—into routine clinical tools that directly inform patient management. Her work supports post-treatment monitoring for haematopoietic stem cell transplantation, gene therapy, and targeted antibody-based interventions.

As a leader in cell therapy, she has overseen the implementation of advanced cellular manufacturing processes and supervised the clinical authorization of personalized therapeutic products. Her career integrates immunogenetics, translational science, and cellular therapy innovation, significantly shaping clinical practice for paediatric patients with rare and complex immune disorders.

Profiles: Scopus | Orcid

Featured Publications:

  • Maimaris, J., Roa-Bautista, A., Sohail, M., et al. (2025). Griscelli Syndrome Type 2: Comprehensive analysis of 149 new and previously described patients with RAB27A deficiency. Journal of Clinical Immunology, 45(50).

  • Author(s) Unknown. (2025). Safety and diagnostic utility of brain biopsy and metagenomics in decision-making for patients with inborn errors of immunity (IEI) and unexplained neurological manifestations. Journal of Clinical Immunology, 45, 86.

  • Booth, C., Masiuk, K., Vazouras, K., Fernandes, A., Xu-Bayford, J., Campo Fernandez, B., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., Reid, J., Gilmour, K. C., Adams, S., Mediavilla, E. A., Mhaldien, L., O’Toole, G., Ahmed, R., Garabedian, E., Malech, H., De Ravin, S. S., Moore, T. B., De Oliveira, S., Pellin, D., Lin, T.-Y., Dang, T. T., Cornetta, K., Hershfield, M. S., Hara, H., Thrasher, A. J., Gaspar, H. B., & Kohn, D. B. (2025). Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency. New England Journal of Medicine, 393(15), 1486–1497.

  • Guardo, D., Mishra, A. K., Rashed, H., Gilmour, K. C., Adams, S., Pinner, D., Sauer, M., Vora, A., Veys, P., Pavasovic, V., Rao, K., & Qasim, W. (2025). Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center. Blood Advances, 9(18), 4750–4754.

 

Willa Hsueh | Immunometabolism | Best Researcher Award

Published on by Cell Biologist

Prof. Willa Hsueh | Immunometabolism | Best Researcher Award

The Ohio State University | United States

Dr. Willa Hsueh is a leading researcher in endocrinology, diabetes, and metabolism, with a career spanning several decades of pioneering contributions to hormone regulation and metabolic disease. Her early research provided key insights into renin biochemistry and aldosterone metabolism, particularly focusing on inactive “big renin” forms and their activation mechanisms in normal and pathological conditions such as diabetic nephropathy. Dr. Hsueh’s investigations have significantly advanced the understanding of the renin-angiotensin-aldosterone system (RAAS) and its role in blood pressure regulation, sodium balance, and endocrine disorders. Her studies explored adrenal physiology, steroid metabolism, and hormonal responses to physiological and pharmacological stimuli, laying the groundwork for later research on cardiovascular and metabolic dysfunctions in diabetes. Through her interdisciplinary approach combining endocrinology, nephrology, and metabolism, she has elucidated biochemical pathways linking hormonal imbalances to metabolic diseases. Dr. Hsueh continues to lead impactful research in diabetes and metabolic regulation, contributing to translational advancements that bridge molecular mechanisms with clinical applications for improved patient outcomes in endocrine and metabolic disorders.

Profiles: Scopus | Orcid

Featured Publications:

Hsueh, W. A., Boonjaren, S., Stein, J., Baehler, H. R., Osgood, R. W., Cohen, S., Yashon, D., & Ferris, T. (1974). Effect of plasma sodium concentration on diluting segment sodium reabsorption. Kidney International, 5(1), 1–11.

Johnson, K. R., Hsueh, W. A., Glusman, S. M., & Arnett, F. C. (1976). Fibrous myopathy: A rheumatic complication of drug abuse. Arthritis & Rheumatism, 19(5), 923–926.

Hsueh, W. A., & Hsu, T. H. (1978). Thyrotoxicosis in a patient with secondary hypothyroidism. Southern Medical Journal, 71(9), 1174–1177.

Hsueh, W. A., Luetscher, J. A., Carlson, E., & Grislis, G. (1978). Big renin in plasma of healthy subjects on high-sodium intake. The Lancet, 1(8077), 1281–1284.

Hsueh, W. A., Hsu, T. H., & Federman, D. D. (1978). Endocrine features of Klinefelter’s syndrome. Medicine, 57(5), 447–461.

Hsueh, W. A., Luetscher, J. A., Carlson, E., Grislis, G., Elbaum, D., & Chavarri, M. (1978). A comparison of cold and acid activation of big renin and of inactive renin in normal plasma. Journal of Clinical Endocrinology and Metabolism, 47(4), 792–799.

Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Published on by Cell Biologist

Mrs. Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Mrs. Alaka Sahoo, Siksha’O’ Anusandhan University, India

Dr. Alaka Sahoo is a dedicated young researcher in the field of Biotechnology with a focus on translational and clinical research. She holds a Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Odisha, with a CGPA of 8.90. With over 17 publications, including 11 research articles and 3 high-impact reviews, Dr. Sahoo has significantly contributed to oral disease therapeutics and antimicrobial studies. She demonstrates expertise in multi-omics analysis, drug discovery, and natural product-based therapy. A recipient of prestigious awards such as the Lalchand Women Entrepreneurs Award (2024), she is also a life member of reputed organizations like the British Society for Antimicrobial Chemotherapy. Her innovative approach to disease management using phytochemicals and peptides sets her apart as a rising talent in biomedical research.

Publication Profile: 

Google Scholar

Scopus

Orcid

✅ Strengths for the Award:

  1. Strong Publication Record:

    • 17 publications including 11 original research, 3 reviews, and 2 book chapters, showcasing depth and breadth.

    • 7 papers as first or corresponding author—indicating independent research capability.

    • Research in high-impact journals like Frontiers in Microbiology, Journal of Ethnopharmacology, Nanomaterials, and Chemistry & Biodiversity.

  2. Innovative & Multidisciplinary Research:

    • Integrates multi-omics, computational modeling, clinical dermatology, and natural products.

    • Focus on oral inflammatory diseases, antimicrobial peptides, and drug delivery systems.

  3. Academic Excellence & Research Training:

    • Ph.D. with 8.90 CGPA, and M.Sc. with 87.07% marks.

    • Expertise in BSL-2+ lab work, PCR, ELISA, microbial culture, and molecular docking.

  4. Awards & Recognition:

    • Lalchand Women Entrepreneurs Award (2024).

    • MSME-Idea Hackathon Innovation Award, Govt. of India.

  5. Global and National Engagement:

    • Life member of the British Society for Antimicrobial Chemotherapy (UK).

    • Demonstrates leadership in science entrepreneurship and women in research.

🛠️ Areas for Improvement:

  1. Expanded International Collaboration:

    • Building long-term research partnerships with international labs could increase global visibility.

  2. Patent/Technology Transfer Efforts:

    • While publications are strong, translating research into patents or commercial products will further strengthen applied impact.

  3. Focused Project Leadership:

    • Leading large interdisciplinary projects or acquiring independent grants will showcase funding leadership.

🎓 Education:

Dr. Alaka Sahoo has pursued a progressive academic path in Biotechnology. She earned her Ph.D. in Biotechnology from the School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed University, Odisha, completing her research with a notable 8.90 CGPA. Her thesis focused on “Therapeutic Opportunities for Oral Lichen Planus: An Integrated Multi-Omics Approach to Drug Discovery” under the guidance of Prof. (Dr.) Maitreyee Panda. Prior to this, she completed her M.Sc. in Biotechnology (87.07%) from the College of Basic Science and Humanities, OUAT, Bhubaneswar in 2018 and a B.Sc. in Biotechnology with distinction (75%) from Ramadevi Women’s College, Utkal University in 2016. Her academic journey showcases a strong foundation in both theoretical and applied aspects of biosciences.

💼 Experience:

Dr. Alaka Sahoo brings rich hands-on research experience in clinical and experimental biotechnology. She is skilled in BSL-2+ lab practices, molecular techniques like PCR, gel electrophoresis, microbial culture, ELISA-based diagnostics, and bioinformatics. Her doctoral work integrated multi-omics and computational biology to study inflammatory oral diseases, and her postdoctoral research spans drug delivery and antimicrobial drug discovery. As first or corresponding author in 7 out of 17 publications, she has led collaborative studies with both national and international partners. Dr. Sahoo’s cross-disciplinary knowledge in microbiology, pharmacology, and nanomedicine enhances her problem-solving abilities, making her a versatile researcher. Her ability to bridge clinical dermatology with biotechnology research positions her as an impactful contributor in both healthcare and academic environments.

🏆 Awards & Honors:

Dr. Alaka Sahoo has received notable accolades for her innovation and leadership in science. In 2024, she was awarded the Lalchand Women Entrepreneurs Award by the Odisha Corporate Foundation, recognizing her outstanding contributions in biotech innovation. She also earned the MSME-Idea Hackathon 3.0 (Women) Innovation Award by the Government of India, honoring her practical scientific advancements with societal impact. These awards reflect her dedication to translational research and her vision to develop cost-effective, natural therapies. Dr. Sahoo is also a life member of two esteemed organizations: the British Society for Antimicrobial Chemotherapy (UK) and Bioclues Innovation, Research and Development (India). Her achievements signify her rising prominence in the field and her commitment to addressing public health challenges through integrative research.

🔬 Research Focus:

Dr. Alaka Sahoo’s research focuses on oral inflammatory diseases, natural product therapeutics, and insect-derived peptides as alternatives to conventional antimicrobials. Her Ph.D. thesis explored multi-omics approaches for drug discovery in Oral Lichen Planus, integrating in vitro, in silico, and clinical data. Her work spans immunomodulation, anti-inflammatory drug screening, and nanodrug delivery systems, with cross-functional expertise in dermatology, pharmacology, and microbiology. She combines computational modeling, molecular docking, and wet-lab validation to develop target-specific therapies. Her studies on biofilm inhibition, antifungal peptides, and phytosteroids hold promise for tackling antimicrobial resistance. Through collaborations across academia and healthcare, she aims to translate her lab findings into clinically viable solutions. Her contributions to systematic reviews and molecular simulations further demonstrate her analytical rigor and commitment to evidence-based research.

📚 Publications Top Notes:

  1. 📘 Experimental and clinical trial investigations of phytoextracts in Oral Lichen Planus: A systematic review – J Ethnopharmacol (2022)

  2. 🐞 Insect-derived antimicrobial peptides as novel anti-biofilm agents: A systematic review – Front. Microbiol. (2021)

  3. 💊 Ultraflexible liposome nanocargo for dermal drug delivery – Nanomaterials (2021)

  4. 🌿 Phytochemicals for Oral Lichen Planus: A multi-omics and experimental study – Chem Biodivers (2025)

  5. ⚗️ Carbohydrate-derived N-benzyl aminocyclopentitols with anticancer properties – Carbohydr Res. (2025)

  6. 🧬 Target-specific screening of anti-inflammatory phytosteroids using molecular docking – Steroids (2025)

  7. 🧪 Insect-derived antifungal peptides in Candida management – Int. J. Mol. Sci. (2025)

  8. 🧫 Azo-coumarin-Co(II)-galangin hybrids for multipotential activities – J. Biomol. Struct. Dyn. (2024)

  9. 🧒 Pediatric dermatology case analysis in Eastern India – Indian J. Paediatr. Dermatol. (2024)

  10. 🔬 Schiff/Mannich coumarin derivatives: Antibacterial and anti-biofilm evaluation – RSC Adv. (2024)

🧾 Conclusion:

Dr. Alaka Sahoo is highly suitable for the Research for Young Researcher Award. Her multi-disciplinary expertise, robust research record, and recognition through national awards highlight her as a promising early-career scientist. She combines academic rigor with innovation, and her work has meaningful implications for public health, especially in oral disease therapy, biofilm inhibition, and phytochemical-based drug development.

Xiaoyan Wang | Immunology Cellular Interactions | Best Researcher Award.

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Researcher Award

Ms. Xiaoyan Wang, Fudan University, China

Dr. Xiaoyan Wang is a postdoctoral fellow at Fudan University with a strong foundation in both clinical and basic cardiovascular research. She holds a PhD in Cardiology from Fudan University and is currently advancing her expertise through the Global Clinical Scholars Research Training Program at Harvard Medical School. Her academic journey spans over a decade of progressive education and clinical experience, complemented by multiple high-impact publications. She actively contributes to scholarly communities as an editor for AME Clinical Trials Review and the organizer of an academic communication club. Dr. Wang’s work bridges immunology and cardiology, particularly in understanding immune mechanisms in cardiovascular diseases. She has received several prestigious fellowships and awards, reflecting her strong scientific rigor and leadership. With her multidisciplinary research background and international exposure, Dr. Wang is an emerging leader in cardiovascular translational research and a strong contender for the Best Researcher Award.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation

    • Trained at top-tier institutions including Fudan University and currently enrolled at Harvard Medical School for global clinical research training.

    • Holds a PhD in Cardiology with a solid foundation in both clinical and basic research.

  2. Extensive Research Experience

    • Over a decade of research with a focus on ventricular remodeling, immune mechanisms in cardiovascular diseases, and non-coding RNAs.

    • Published in high-impact journals such as Signal Transduction and Targeted Therapy, Annals of Translational Medicine, and Heliyon.

  3. Recognized Expertise and Leadership

    • Awarded Postdoctoral Fellowship by CPSF and Super Postdoctoral Fellowship by Fudan University in 2023.

    • Section Editor at AME Clinical Trials Review and organizer of the “Excellent Academic Research Communication Club”.

  4. Interdisciplinary and Translational Focus

    • Combines clinical cardiology with molecular immunology, enhancing the translational potential of her research.

  5. Global Perspective

    • Active participation in international research forums like the Japanese Circulation Society, which reflects global relevance.

⚙️ Areas for Improvement:

  • Broader Collaboration: While her core work is well-recognized, expanding interdisciplinary and international collaborations could amplify her visibility.

  • Clinical Trial Leadership: Leading a multi-center clinical trial would significantly strengthen her clinical research credentials.

  • Grant Acquisition: More information on independently secured competitive research grants could further demonstrate leadership.

🎓 Education:

Dr. Xiaoyan Wang is currently enrolled in the Global Clinical Scholars Research Training Program (2024–2025) at Harvard Medical School, combining online and on-site learning. She earned her PhD in Cardiology at Fudan University’s Zhongshan Hospital (2016–2019), where she conducted basic research on ventricular remodeling under Prof. Yunzeng Zou, supported by national-level research funds. Earlier, she obtained her Master’s degree in clinical cardiology from Dalian Medical University (2013–2016), supervised by the esteemed Prof. Yaling Han. Her undergraduate training was completed at Fujian Medical University (2007–2012), where she laid the foundation for her clinical and academic career. Her education reflects a steady progression toward excellence in cardiovascular research, integrating both laboratory and patient-based studies. Dr. Wang’s cross-disciplinary and global educational background equips her with a unique perspective in translational medicine and scientific innovation.

🩺 Experience:

Dr. Xiaoyan Wang is a postdoctoral fellow at Fudan University (2023–present), where she continues her cardiovascular research under Prof. Yunzeng Zou and fosters academic exchange as the organizer of the “Excellent Academic Research Communication Club.” She also serves as a section editor for AME Clinical Trials Review (2024–present). Previously, she worked as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital (2022–2023) and as a cardiovascular specialist at Fudan University’s Zhongshan Hospital (2019–2022). Her clinical practice is complemented by a strong research portfolio and academic leadership. Dr. Wang’s diverse roles reflect her commitment to integrating clinical insight with research innovation. Her responsibilities span research coordination, patient care, publishing, and mentoring, positioning her as a clinician-scientist deeply embedded in academic medicine.

🏆 Awards and Honors:

Dr. Xiaoyan Wang has been recognized with several competitive awards that underscore her research excellence. In 2023, she received the Postdoctoral Fellowship Program of CPSF and was named a Super Postdoctoral Fellow at Fudan University—both high honors recognizing scientific innovation and impact. Her clinical insights and writing skills earned her third prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She was also selected to present at the Late-Breaking Cohort Studies session at the Japanese Circulation Society (JCS) Annual Meeting in 2019, an indication of her work’s international relevance. These awards demonstrate her ability to balance rigorous clinical practice with pioneering research, making her a standout candidate for accolades like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang’s research centers on the intersection of cardiology and immunology, with a special focus on ventricular remodeling, cGAS-STING signaling pathways, immune responses in myocardial infarction, and non-coding RNAs. Her work spans both basic and translational research, investigating the molecular mechanisms behind cardiovascular disease progression while aiming to identify therapeutic targets. She has explored the roles of Akt, β-arrestin-2, CaMKII, and immune gene signatures in heart failure and myocardial infarction. Dr. Wang’s research has practical clinical implications, informing diagnosis and prognosis in cardiovascular medicine. Through international collaborations and cutting-edge methodologies, she contributes to a deeper understanding of immune-cardiovascular crosstalk. Her publication track record and editorial roles affirm her impact in shaping current and future directions in cardiovascular research.

📚 Publications Top Notes: 

1️⃣ 🧬 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications – Signal Transduction and Targeted Therapy (2025)
2️⃣ 🧠 The connection of immune response and cGAS-STING pathway in cardiovascular disease – International Journal of Biological Sciences (Revised)
3️⃣ 🧪 Left ventricular response in the transition from hypertrophy to failure… in mice with aortic regurgitation – Annals of Translational Medicine (2020)
4️⃣ 🩸 The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis – Bioscience Reports (2018)
5️⃣ 🚬 Galectin-3 inhibition alleviates cigarette smoke extract-induced EPC dysfunction by downregulating autophagy – Oxidative Medicine and Cellular Longevity (2019)
6️⃣ 🔁 Circular RNA in cardiovascular disease – Non-coding RNA Investigation (2017)
7️⃣ ❤️‍🔥 An Integrated Signature of Clinical Metrics and Immune-Related Genes as a Prognostic Indicator for STEMI Patient Survival – Heliyon (2024)

🧾 Conclusion:

Dr. Xiaoyan Wang is an exceptionally qualified candidate for the Best Researcher Award. Her research blends clinical relevance with molecular depth, showing a clear trajectory toward academic leadership in cardiovascular immunology. With a combination of high-impact publications, clinical acumen, and global training, she exemplifies the qualities this award seeks to honor. Minor expansions in clinical trial leadership and collaborative reach could further elevate her profile. Nevertheless, her current accomplishments already distinguish her as a top-tier emerging researcher.

Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Prof. Yidong Wei , Shanghai Tenth People’s Hospital, Tongji University , China

Dr. Yidong Wei, M.D., Ph.D., FACC, is a distinguished professor and the Chief of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. He also holds a clinician management role at the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. With a strong foundation in both clinical and translational research, Dr. Wei has built an internationally recognized career focused on interventional cardiology, cardiac electrophysiology, and cardiovascular epidemiology. He is a Fellow of the American College of Cardiology, reflecting his global academic influence. Known for bridging clinical care with bench-side discovery, his work has advanced understanding in myocardial infarction, heart failure, and calcium signaling in cardiomyocytes. With numerous high-impact publications and leadership in multicenter registries like NOAFCAMI-SH, Dr. Wei’s contributions are widely cited and clinically relevant. His dual academic and clinical roles across China and the UK highlight his dedication to innovation, international collaboration, and excellence in cardiovascular medicine.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. High-Impact Research Output:
    Dr. Wei has authored or co-authored more than 18 recent peer-reviewed publications in prestigious journals such as Diabetes Metabolism Research and Reviews, Redox Biology, Cardiovascular Diabetology, and ESC Heart Failure. Many of these works are already cited, indicating early academic impact and relevance.

  2. Dual Focus – Basic and Clinical Science:
    His research bridges the gap between molecular mechanisms (e.g., calcium signaling, TRIM21, PTEN) and clinical cardiology (e.g., atrial fibrillation, myocardial infarction, cardiac remodeling), highlighting a robust translational focus.

  3. Leadership and Collaboration:
    He serves as Chief of Cardiology at Shanghai Tenth People’s Hospital and a Clinician Manager at the University of Oxford, demonstrating international leadership and cross-border collaboration.

  4. Registry Leadership (NOAFCAMI-SH):
    His work through the NOAFCAMI-SH registry provides real-world evidence on cardiovascular disease progression, risk prediction, and treatment response—critical for patient-centered care.

  5. Prestigious Recognition:
    Dr. Wei is a Fellow of the American College of Cardiology (FACC), a title reserved for top-tier cardiovascular professionals with sustained excellence.

⚠️ Areas for Improvement:

  1. Broader International Research Leadership:
    While Dr. Wei has strong China–UK collaborations, leading global multicenter clinical trials or international consortia would further solidify his standing.

  2. Public Engagement and Knowledge Translation:
    Though academically prolific, increased involvement in public health education or policy advocacy could amplify the real-world impact of his research.

  3. Mentorship Track Record Visibility:
    Highlighting mentorship of junior researchers and postdocs more explicitly in profiles and bios would enhance his case for a holistic academic leadership award.

🎓 Education:

Dr. Wei began his medical education at Henan Medical University, where he completed clinical training with a focus on cardiovascular medicine. Driven by a passion for research, he pursued and completed his Ph.D. in 2004, with a specialization in cardiac electrophysiology and calcium signaling pathways. His graduate studies were complemented by advanced basic science training at the University of Kentucky, USA, a leading institution in biomedical research. Between 2004 and 2006, Dr. Wei completed postdoctoral research, focusing on the molecular mechanisms of cardiac dysfunction and electrophysiology. His educational background reflects a balanced integration of rigorous clinical education and innovative research development, equipping him with the tools necessary to bridge bedside care with laboratory insights. This foundation has allowed Dr. Wei to contribute to both academic medicine and cutting-edge cardiovascular research, distinguishing him as a leader with comprehensive and global training in the field.

🏥 Experience:

With over two decades of experience, Dr. Yidong Wei serves as Professor and Chief of the Department of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. His role extends internationally, acting as Clinician Manager at the University of Oxford’s Centre for Diabetes, Endocrinology and Metabolism. His clinical expertise spans interventional cardiology, acute coronary syndromes, and electrophysiological interventions, while his research roles emphasize trial design, biomarker discovery, and cellular cardiology. He has led and contributed to large-scale registries like NOAFCAMI-SH, generating evidence that informs guidelines for myocardial infarction and atrial fibrillation. His professional experience combines healthcare leadership, cross-border academic collaboration, and impactful research. As a Fellow of the American College of Cardiology, he is actively engaged in academic societies and peer-reviewed journals. Dr. Wei’s experience reflects an enduring commitment to patient care, innovation in research, and mentorship of future cardiology leaders, marking him as a high-impact contributor in his field.

🔬 Research Focus:

Dr. Yidong Wei’s research lies at the intersection of clinical cardiology and molecular medicine. He focuses on interventional cardiology, atrial fibrillation, myocardial infarction, and calcium signaling pathways in cardiac myocytes. A major theme in his work is the electrophysiological basis of heart failure and age-related changes in ventricular function. Using techniques like patch clamping, calcium imaging, laser confocal microscopy, and molecular biology, he investigates calcium channel regulation and excitation-contraction coupling in cardiac cells. Clinically, he leads research through the NOAFCAMI-SH registry, analyzing systemic inflammation, hyperglycemia, atrial fibrillation, and long-term cardiac outcomes. His work advances the understanding of post-infarction remodeling and atrial pathology. Combining basic science with real-world data, Dr. Wei’s research bridges gaps in translational cardiology and offers therapeutic targets for chronic cardiac conditions. His integrative approach makes him a pioneer in translating bench findings into bedside impact, with potential to redefine cardiac care strategies globally.

📚 Publications Top Notes:

  1. 📈 Association of stress hyperglycemia ratio with atrial fibrillation and outcomes in myocardial infarction

  2. 🧪 Prognostic implications of systemic immune-inflammation index in MI patients with and without diabetes

  3. 🧬 TRIM21 deficiency protects heart post-MI by reducing oxidative stress

  4. 🫀 4S-AF scheme for characterizing atrial fibrillation after myocardial infarction

  5. 🔬 TRIM21 worsens cardiac injury via M1 macrophage polarization post-MI

  6. 🧮 Stress hyperglycemia and outcomes in MI with and without diabetes mellitus

  7. 💉 ZPI protects endothelium via PI3K/Akt pathway activation against ox-LDL

  8. 📊 Atrial fibrillation’s prognosis across heart failure subtypes post-MI

  9. 🕒 Five-year outcomes post left atrial appendage occlusion

  10. 🧫 PTEN and serum deprivation-induced cytotoxicity via PI3K/AKT pathway

🧾 Conclusion:

Dr. Yidong Wei stands out as a highly suitable candidate for the Best Researcher Award. His contributions to cardiovascular research—spanning cutting-edge basic science to influential clinical trials—are both innovative and impactful. His leadership roles, international presence, and translational focus align perfectly with the goals of this prestigious recognition. Given his trajectory, Dr. Wei is not only a leader in current cardiovascular research but also a driver of future scientific breakthroughs.

Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Published on by Cell Biologist

Dr. Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Dr. Laure VINCENT, CHU de Montpellier , France

Dr. Laure Vincent is a distinguished hematologist at the CHU de Montpellier, specializing in clinical hematology. With a focus on multiple myeloma and stem cell transplantation, she is recognized for her extensive research and clinical expertise. She is affiliated with the Hôpital St Eloi, Montpellier, where she actively contributes to advancing treatments in hematologic malignancies. Dr. Vincent has a profound commitment to patient care and an established career in the hematology field, making notable contributions to both the scientific and medical communities.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Contribution: Dr. Vincent has made significant contributions to the field of hematology, with numerous publications in renowned journals such as Leukemia, Bone Marrow Transplantation, Haematologica, and Blood Cancer Journal. Her research has focused on critical topics like multiple myeloma, hematopoietic stem cell transplantation, and the treatment of myelodysplastic syndromes.

  2. Innovative and Impactful Studies: Many of her studies highlight novel findings that contribute to the understanding and management of hematological diseases. For instance:

    • Her research on insulin as a myeloma cell growth factor (Leukemia, 2010) opened new avenues for treatment approaches.

    • The exploration of the therapeutic window for myeloma relapse after high-dose melphalan and stem cell transplantation (Oncotarget, 2012) shows an in-depth understanding of patient care in a post-transplant setting.

    • The retrospective study on hematopoietic stem cell transplantation in multiple myeloma patients from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (Biol Blood Marrow Transplant, 2015) has crucial implications for treatment strategies in myeloma.

  3. Multidisciplinary Collaboration: Dr. Vincent has worked extensively with international research teams, reflecting her ability to collaborate and contribute to large-scale studies and multicenter trials. This is evident in studies such as the ones published with the Société Française de Greffe de Moelle et de Thérapie Cellulaire and the Eurocord/ALWP-EBMT study.

  4. Comprehensive Educational Impact: In addition to her research, Dr. Vincent has contributed significantly to the education and training of healthcare professionals, particularly in oncology and hematology. Her work in developing educational content for nurses and students in the field of Onco-Hematology demonstrates her commitment to advancing clinical knowledge.

Areas for Improvement:

  1. Wider Dissemination of Findings: While Dr. Vincent’s research has been highly impactful within the specialized field of hematology, her findings could benefit from broader dissemination. This could include collaborations with non-medical fields or publishing findings in more general medical journals to reach a wider audience.

  2. Focus on Translational Research: Although Dr. Vincent’s research primarily focuses on clinical outcomes and therapies, incorporating more translational research—bridging the gap between bench and bedside—could further enhance her work. Research on biomarkers for early detection, for example, would benefit the field of personalized medicine.

  3. Long-Term Impact Studies: Some of Dr. Vincent’s studies are focused on the immediate or short-term effects of therapies. It would be valuable to see more research that addresses the long-term outcomes of treatments in hematological diseases, especially in terms of quality of life and survival rates over decades.

Education:

Dr. Vincent’s educational journey began with secondary studies at the Lycée International de Grenoble, where she earned a scientific baccalaureate with distinction in 1999. She then pursued her medical degree at the University of Grenoble (1999-2006), followed by specialized training in hematology. Dr. Vincent is fluent in English, holding Cambridge Certificates in Advanced and Proficiency English. Additionally, she holds certifications in business English and advanced clinical training in hematology.

Experience:

Dr. Laure Vincent has extensive clinical experience in the field of hematology, particularly in hematopoietic stem cell transplantation. She has contributed to several impactful research studies, focusing on treatments for hematological malignancies like multiple myeloma and myelodysplastic syndromes. Dr. Vincent has published extensively in reputable journals, authored chapters in medical books, and presented her work at various prestigious international conferences, demonstrating her authority in the field. She also serves as an educator, contributing to the training of future healthcare professionals.

Research Focus:

Dr. Vincent’s research primarily focuses on hematological cancers, including multiple myeloma, myelodysplastic syndromes, and stem cell transplantation. Her studies explore innovative therapies, relapse prevention strategies, and mechanisms of drug resistance in these malignancies. Notable research topics include the use of monoclonal antibodies, the role of the bone marrow microenvironment, and the improvement of outcomes following hematopoietic stem cell transplantation. Her work aims to develop targeted therapies to improve patient survival rates and quality of life.

Publications Top Notes:

  1. “Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation” (Leukemia, 2010) 🧬

  2. “Malignant plasma cells responsible for Multiple Myeloma relapse are detectable and survive seven days after high dose melphalan and stem cell transplantation” (Oncotarget, 2012) 🧪

  3. “Allo-SCT for philadelphia negative myeloproliferative neoplasms in blast phase” (Bone Marrow Transplant, 2014) 💉

  4. “HLA-matched Allogeneic SCT improves outcome of higher risk MDS” (Leukemia, 2015) 🩸

  5. “Drug metabolism and clearance system in tumor cells of patients with multiple myeloma” (Oncotarget, 2015) 💊

  6. “Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation” (Haematologica, 2015) 👩‍⚕️

  7. “Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia” (Leukemia, 2015) 🔬

  8. “Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study” (Biol Blood Marrow Transplant, 2015) 🏥

  9. “Autologous Stem Cell Transplantation For Relapsed/Refractory Diffuse Large B Cell Lymphoma” (Bone Marrow Transplant, 2015) 🔄

  10. “Bing-Neel syndrome as a rare complication of Waldenström’s macroglobulinemia” (Haematologica, 2015) 🧠

Conclusion:

Dr. Laure Vincent’s research is exceptional, with a proven track record in advancing knowledge and treatment options in hematology. Her ability to lead large-scale studies, her contributions to important clinical findings, and her dedication to educating future healthcare professionals make her highly deserving of the “Best Research Article Award.” While there is always room for expanding the scope of research to include more translational and long-term impact studies, her work undoubtedly stands out as a significant contribution to hematological science.

Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Prof. Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China

Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.

Publication Profile:

Scopus

Strengths for the Award:

  1. Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
  2. Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
  3. Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
  4. Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.

Areas for Improvement:

  1. Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
  2. Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
  3. Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.

Education:

Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.

Experience:

Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.

Research Focus:

Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.

Publications Top Notes:

  • The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
  • Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
  • Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
  • Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
  • Extracellular Vesicle‐Based Nanodrug Delivery 💊
  • Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
  • Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
  • Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
  • Smart delivery of poly-peptide composite for effective cancer therapy 💡
  • The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️

Conclusion:

Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.

 

 

 

Isabelle Brigaud | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mrs. Isabelle Brigaud | Immunology Cellular Interactions | Best Researcher Award

Mrs. Isabelle Brigaud , CNRS IS2M , France

Isabelle Brigaud is an experienced research engineer at CNRS IS2M, Mulhouse, France. With a strong foundation in molecular biology, biochemistry, cell biology, and bioinformatics, she specializes in the study of biomaterials, tissue engineering, and immunology. Brigaud has made significant contributions to understanding the foreign body response to materials such as silicone breast implants and injectable hydrogels. Her expertise spans molecular cloning, protein analysis, and the development of study models using ex vivo, animal models (e.g., zebrafish, Drosophila, and Spodoptera littoralis), and advanced imaging techniques like confocal microscopy. Passionate about collaborative research, she is involved in managing cross-functional projects, fundraising, and mentoring students. Brigaud holds CNU qualifications in cell biology and physiology and is an advocate for continuous technical training. Her research has resulted in numerous high-impact publications in the field of biomaterials and molecular biology.

Publication Profile:

Orcid

Strengths for the Award:

  1. Diverse and High-Impact Research Focus: Isabelle Brigaud’s research spans multiple biological disciplines, including molecular biology, biochemistry, cell biology, and biophysics, showing a broad and in-depth understanding of biological processes. This is particularly demonstrated through her contributions to studies in immunogenic responses in breast implant tissue, the molecular mechanisms of endometriosis, and cellular interactions with biomaterials, indicating her versatility in tackling diverse biological challenges.
  2. Strong Publication Record: Brigaud has a consistent publication history in high-impact journals, such as Biomaterials, Nature Communications, Acta Biomater, and PRS. These publications focus on important topics like cellular migration, biomaterial interaction, and regenerative medicine, all of which are at the forefront of current biomedical research. Her work on the interaction of biomaterials with tissues, especially focusing on inflammatory responses, positions her as a leading researcher in the field.
  3. Expertise in Advanced Techniques: She is proficient in a wide range of cutting-edge techniques, from molecular biology techniques like RNAseq and PCR to cell biology methods, including cell differentiation and functional pharmacology. This technical expertise is key for producing reliable, reproducible results, which is crucial for advancing scientific knowledge.
  4. Cross-Disciplinary Collaboration: Brigaud’s experience in collaborating across various research teams, institutions, and international boundaries highlights her ability to contribute effectively to multidisciplinary research projects. She has also demonstrated leadership in supervising and training students and researchers, underscoring her role as a mentor and leader in the research community.
  5. Management and Funding Expertise: As a research engineer and project manager, she has led several important projects, such as those related to soft tissue reactions to implants and muscle regeneration. Her experience in fundraising and project management indicates strong organizational and leadership skills, both of which are crucial for steering complex research initiatives toward success.
  6. Commitment to Health-Related Research: Her work on health-related issues, such as the effects of silicone breast implants on immune responses and the management of endometriosis symptoms through exercise, shows a direct impact on improving human health. Her research addresses real-world health challenges, making it highly relevant and applicable to clinical settings.

Areas for Improvement:

  1. Broader Dissemination of Findings: While Brigaud has an impressive publication record, there is a potential for more dissemination of her findings to the broader scientific community, especially through high-visibility conferences and workshops. Increased visibility could attract more collaborative opportunities and funding for her projects.
  2. Expanding Research Focus on Novel Therapeutic Applications: Brigaud’s research has already significantly contributed to understanding biomaterials and cell interactions. Further expansion into therapeutic applications, such as designing and testing novel drug delivery systems or regenerative therapies, could strengthen her profile as a researcher with direct clinical and pharmaceutical applications.
  3. Increased Focus on Large-Scale Collaborative Projects: While Brigaud has demonstrated leadership in individual projects, engaging in larger, multi-institutional collaborative projects could provide even more resources and amplify the impact of her research on a global scale.
  4. Enhancing Outreach to Broader Audiences: Given her expertise in addressing important clinical and biomedical issues, there may be an opportunity for Brigaud to engage with broader non-specialist audiences, including through public science communication platforms, to make her work more accessible to the general public.

Education:

Isabelle Brigaud holds a PhD in Molecular Biology and Insect Physiology from Jussieu, Paris VI, awarded with first-class honors in 2008. She also completed a Master 2 in Integrative Biology and Physiology, specializing in adaptation to the environment, and a Master 1 in Population and Ecosystem Biology and Ecophysiology, both from Jussieu, Paris VI, with honors. Brigaud has expanded her academic credentials with postdoctoral research experiences at the University of Freiburg, Germany (2012-2014), focusing on the cytoskeleton organization in zebrafish development. Prior to that, she conducted research at CNRS/INSERM in Lyon, France (2009-2011), where she studied the plasticity of cell morphology during Drosophila oogenesis. Her academic journey reflects a deep commitment to understanding molecular biology, cell biology, and biochemistry, which has shaped her research trajectory and expertise in biomaterials and tissue engineering.

Experience:

Isabelle Brigaud has extensive experience in molecular biology, cell biology, and biochemistry. She has worked at CNRS IS2M, Mulhouse, France, since 2019 as a research engineer, managing biomolecule platforms and leading studies on the foreign body response to silicone implants and injectable hydrogels. Brigaud previously held postdoctoral research positions at the University of Freiburg, Germany, and CNRS/INSERM, Lyon, France, where she investigated cytoskeletal dynamics in zebrafish lateral line development and cell morphology plasticity during Drosophila oogenesis. During her PhD at INRAE, Versailles, she focused on pheromone detection mechanisms in pest moths, an experience that formed her expertise in molecular biology and insect physiology. In addition to her hands-on research, Brigaud is involved in cross-functional project management, collaborative teamwork, and student supervision, demonstrating strong leadership skills and a passion for advancing scientific knowledge.

Awards and Honors:

Isabelle Brigaud’s work has been recognized through several prestigious publications and her contributions to the fields of biomaterials and molecular biology. Her research on the foreign body response to silicone breast implants and injectable hydrogels has made significant strides in understanding tissue regeneration and inflammatory responses. As an active member of the research community, she has been involved in multiple high-impact journal articles published in prominent scientific journals such as Biomaterials, Acta Biomaterialia, and Nature Communications. Although specific awards are not detailed in her profile, her extensive publication record, including multiple first-author and co-author contributions, highlights her ongoing influence in the scientific community. Brigaud’s commitment to advancing knowledge in biomaterials, molecular biology, and tissue engineering is further demonstrated through her leadership roles in cross-disciplinary projects, mentoring students, and managing research collaborations.

Research Focus:

Isabelle Brigaud’s research focuses on the intersection of molecular biology, biomaterials, and tissue engineering, with a specific interest in understanding the foreign body response to implants and regenerative therapies. Her work explores the immune reactions induced by materials like silicone breast implants and injectable hydrogels, aiming to improve tissue regeneration and reduce inflammation. Brigaud’s expertise includes molecular cloning, protein analysis, cell culture, and advanced imaging techniques, all of which she applies to study cell behavior, tissue interactions, and the effects of materials on cellular processes. She uses animal models, including zebrafish and Drosophila, to investigate cell morphology plasticity and mechanotransduction. Her focus also extends to the development of drug delivery systems and the role of extracellular matrix in inflammation and tissue healing. Brigaud’s collaborative approach to research has led to significant advances in the study of immunology, regenerative medicine, and biomaterials.

Publications Top Notes:

  • Brigaud I et al., 2024. Breast implant silicone exposure induces immunogenic response and autoimmune markers in human periprosthetic tissues. Biomaterials 🔬💉
  • Ouedraogo C et al., 2024. Fabrication and characterization of thin self-rolling film for anti-inflammatory drug delivery. Colloids Surf B Biointerfaces 💊🧬
  • Escriva-Boulley G et al., 2023. Effects of physical activity and endometriosis-based education program delivered by videoconference on endometriosis symptoms: the CRESCENDO program. Trials 🏃‍♀️🩺
  • Brigaud I et al., 2020. Surface texturization of breast implants impacts extracellular matrix and inflammatory gene expression in asymptomatic capsules. PRS 🦠🔬
  • Wakhloo NT et al., 2019. Actomyosin, vimentin and LINC complex pull on osteosarcoma nuclei to deform on micropillar topography. Biomaterials 🦴🔬
  • Pieuchot L et al. 2018. Curvotaxis directs cell migration through cell-scale curvature landscapes. Nature Commun. 🌍🧬
  • Brigaud I et al. 2017. Synergistic effects of BMP-2, BMP-6 or BMP-7 with human plasma fibronectin onto hydroxyapatite coatings: A comparative study. Acta Biomater. 🧫
  • Brigaud I et al., 2015. TGFbeta/activin signaling induces epithelial cell flattening during Drosophila oogenesis. Biol Open 🦗💡
  • Montagné N et al., 2012. Functional characterization of a sex pheromone receptor in the pest moth Spodoptera littoralis by heterologous expression in Drosophila. European Journal of Neuroscience 🦋👃
  • Montagne N et al.,2011. Functional characterization of a sex pheromone receptor in the pest moth Spodoptera littoralis. Chemical Senses 🦋💨
  • Brigaud I et al., 2009. Identification of an atypical insect olfactory receptor subtype highly conserved within noctuids. FEBS Journal 🦗👃
  • Brigaud I et al. 2009. Cloning and expression pattern of a putative octopamine/tyramine receptor in antennae of the noctuid moth Mamestra brassicae. Cell and Tissue Research 🦋🧬

Conclusion:

Isabelle Brigaud is undoubtedly a strong contender for the Research for Best Researcher Award. Her multifaceted expertise, robust publication record, and impactful contributions to molecular biology, cell biology, and biochemistry, particularly in the context of health applications, position her as a leader in her field. With her proven ability to manage large-scale research projects and mentor the next generation of scientists, she continues to make significant strides in biomedical research. By focusing on increasing the visibility of her findings and expanding her research into therapeutic domains, Brigaud could further elevate her already outstanding career.